Compound
← Compound
Official website →
BSXBoston Scientific Corp
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- BSX
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three pr…
IndustryMedical - Devices
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
17.48×
P/B
Price divided by book value
2.57×
EV/EBITDA
Enterprise value divided by operating cash generation
13.47×
EV/Revenue
Enterprise value divided by revenue
3.64×
What the company earns
ROE
Return on shareholders’ equity
14.9%
ROA
Return on all assets
8.1%
Gross margin
What remains after product costs
71.2%
Operating margin
What remains after operating the business
21.5%
Net margin
How much of each revenue unit becomes profit
17.5%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
0.51
Total debt
Sum of borrowings
$12.62B
Cash
Cash available to cover it
$539M
Current ratio
Short-term assets divided by short-term liabilities
1.24
Free cash flow
Cash left after investing
$1.28B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.57
Revenue growth
Compared with the same period a year earlier
7.5%
Earnings growth
Compared with the same period a year earlier
14.4%
Dividend yield
Trailing 12-month distributions divided by price
0%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 12.68B | 14.24B | 16.75B | 20.07B |
| Custo dos produtos | -3.96B | -4.35B | -5.26B | -6.22B |
| Lucro bruto | 8.73B | 9.9B | 11.49B | 13.85B |
| Despesas com vendas e administrativas | -4.52B |
News about BSX
Yahoo Finance · 3 days ago
Thermo Fisher Scientific (TMO) is Positioned for Resurgence
The article’s case for a resurgence rests on a sequence: post-COVID normalization and concerns about pharmaceutical funding weighed on recent performance, while recurring revenue and ongoing demand in drug discovery and production are presented as support for renewed growth. The source also reports that 118 hedge fund portfolios held the stock at the end of the second quarter, compared with 115 in the previous quarter. These are the article’s cited arguments and ownership data, not a guarantee of future results.
Seeking Alpha · 4 days ago
Boston Scientific downgraded at Citi on increasing competition, cyberattack fallout
PR Newswire · 4 days ago
Michael J. Fox Foundation Announces $2.5 Billion "All Grit. No Quit." Campaign to Accelerate Parkinson's Breakthroughs
Investing.com · 4 days ago
Citi downgrades Boston Scientific on uncertain recovery path
Follow BSX and get agent analysis of what is moving the stock.
Open Compound